The Original BARK Company Common Stock BARK 深 滬
已收盤 12-12 16:00:00 美东时间
0.6613
-0.015
-2.19%
華盛通- 最 高0.694
- 今 開0.66
- 成交量 50.02万股
- 最 低 0.66
- 昨 收 0.6761
- 總市值 1.12亿
- 52周最高 2.315
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 0.6268
- 委 比 -80.00%
- 總股本 1.70亿
- 歷史最高 19.54
- 量 比 0.83
- 振 幅 5.03%
- 歷史最低 0.6268
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BARK Sees Q3 Sales $101.000M-$104.000M vs $106.485M Est
BARK (NYSE:BARK) sees Q3 sales of $101.000 million-$104.000 million vs $106.485 million analyst estimate.
11-10 20:05
BARK Q2 Adj. EPS $(0.03) Misses $(0.01) Estimate, Sales $106.970M Beat $103.515M Estimate
BARK (NYSE:BARK) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 400 percent decrease over earnings of $0.01 per share from the same period
11-10 20:05
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...
10-27 20:30
Reported Sunday, Pfizer And Astellas Report 40% Lower Risk Of Death With XTANDI Plus Leuprolide Versus Leuprolide Alone In Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical
10-20 15:41
BARK CEO Shifts Focus From Institutional to 'Sophisticated Retail Investors' On X And Discord, Saying They Drive 'Performance Of A Stock Much More'
BARK's CEO explains his pivot from institutional funds to engaging retail investors on X and Discord. Learn his new market strategy.
10-09 03:24
Pfizer To Highlight Data Across Its Oncology Portfolio, Including Five Late-Breaking Presentations And Recognition In Presidential Symposium, At ESMO Congress 2025
More than 45 abstracts, including five late-breaking presentations and recognition in Presidential Symposium, showcase impact of approved medicines and potential of next-generation pipeline
09-25 18:47
BARK Inc Promotes Michael Black to President
The latest announcement is out from BARK Inc Class A ( ($BARK) ). On September ...
09-04 05:47
Insights into Sportsman's Warehouse's Upcoming Earnings
Sportsman's Warehouse (NASDAQ:SPWH) is preparing to release its quarterly earni...
09-04 00:02
Shares of retail companies and consumer stocks are trading lower amid overall market weakness after Walmart reported mixed Q2 financial results. Investor concern about the economy may be weighing down the sector following yesterday's Fed minutes and today's Jobless Claims economic data.
Shares of retail companies and consumer stocks are trading lower amid overall m...
08-22 01:06
